LITTLETON, Colorado—Vivos Therapeutics, Inc. (the “company” or “Vivos”) a medical technology company focused on developing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, has signed a U.S. nationwide distribution agreement with Lincare, a leading supplier of in-home respiratory therapy products and services for approximately 1.8 million patients.
The agreement follows the successful conclusion of a distribution pilot with Lincare, and marks an important milestone in Vivos’ strategy to engage with leading durable medical equipment (DME) companies in the United States. Vivos has agreed that Lincare will have a six-month exclusivity to distribute certain designated Vivos devices.
“We are pleased to offer oral appliances as an alternative treatment to our non-compliant CPAP patients," Jeff Barnhard, CEO of Lincare, said. "Finding the best solutions for our sleep apnea patients has always been a high priority for Lincare. We look forward to working alongside Vivos-trained dentists.”
“Across the United States, hundreds of thousands of new CPAP units are rented or sold through DME companies each month," said Kirk Huntsman, chairman and CEO of Vivos. "Lincare is one of the market leaders in this sector, and we are pleased to join forces with them in this pioneering initiative. It is well known that a sizable number of sleep apnea patients discontinue CPAP usage in search of alternative treatment options. This important collaboration between a national supplier of DME like Lincare and an innovative oral appliance company like Vivos will bring fresh solutions and relief to patients currently seeking alternatives. Our pilot trial allowed both parties time to work through the program logistics, including the development of a new Vivos proprietary software to manage DME patients and scale to a national level.
“As we move forward, we see these types of agreements as a key component in Vivos’ quest to achieve positive cash flows over the next year," Huntsman continued. "We are currently focused on extending the scope of our efforts with Lincare to the next five major markets, with additional markets to follow according to a rollout schedule over the next 6-12 months.”
